For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

BPC-157

Also known as: Body Protection Compound 157, PL 14736

Research use only · not FDA-approved

Pentadecapeptide derived from a gastric protective protein. Studied for tendon/ligament healing, GI tract repair, and angiogenesis via VEGFR2 pathway interaction.

Where to buy · live market data

Who's worth your money for BPC-157

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 37 scored sellers

$2.30/mg

$45.99 · 20mg · 100.0% purity

10 COAs
Buy code MERIT · 10% off

Best value after code

$0.06/mg effective with 15% code

$0.07/mg

$0.36 · 5mg · 99.6% purity

12 COAs
Buy code MERIT · 15% off

Most tested

91 independent COAs on file

$3.18/mg

$31.80 · 10mg · 99.8% purity

Average price

$8.44/mg

Sellers

91

45-day trend

+0.2%

72 of 91 sellers have a current price· 24 stale hidden· 11 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch BPC-157

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About BPC-157

CAS

137525-51-0

Molecular formula

C62H98N16O22

Sequence

GEPPPGKPADDAGLV

Typical dose range

200-500 mcg/day subcutaneous or intramuscular

Half-life

<30 minutes (IV: ~15 min in rats, ~5 min in dogs)

Common research uses

tendon and ligament injury recoverygastrointestinal ulcer healing (animal studies)post-surgical recovery (research only)

Safety notes

Not FDA-approved for human therapeutic use. WADA does not currently prohibit BPC-157 but research-use only status applies in most jurisdictions.

Reconstitution

Reconstitute lyophilized powder with bacteriostatic water; refrigerate after reconstitution.

Independent evidence

COAs for BPC-157

517 third-party tests across 60 vendors. Each card links to the full report.

All 517 COAs for BPC-157 →
Measured purity 76.3%–100.0% across 323 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.72 %
Jul 2026
ILS Labs Strong

For

BPC-157

by Voltera Sciences· batch BC10-07082026

Aggregated · 3rd-party listing
99.56 %
Jul 2026
Freedom Diagnostics Moderate

For

BPC-157

by Peptide Plugs· batch 161-620L-DK

Aggregated · 3rd-party listing
99.90 %
Jul 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch BPC10-08

Aggregated · 3rd-party listing
99.42 %
Jul 2026
Freedom Diagnostics Moderate

For

BPC-157

by Modern Research Peptides· batch EV24338MON

Aggregated · 3rd-party listing
99.00 %
Jul 2026
Ethos Analytics Strong

For

BPC-157

by OROS Research· batch OR-LPBPC5-626-B6

Aggregated · 3rd-party listing
99.91 %
Jul 2026
Freedom Diagnostics Moderate

For

BPC-157

by Peptide Plugs· batch 148-01-DK

✓ Vendor-published
99.51 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Ion Peptide· batch BCS-06242026

COA on file
Aggregated · 3rd-party listing
99.91 %
Jun 2026
ILS Labs Strong

For

BPC-157

by Orbitrex Peptides· batch BPC10726US

Aggregated · 3rd-party listing
99.51 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Ion Peptide· batch BC5-06242026

Aggregated · 3rd-party listing
99.64 %
Jun 2026
Janoshik Analytical Limited

For

BPC-157

by Optima Supply· batch OS-2026-3074

Aggregated · 3rd-party listing
99.64 %
Jun 2026
Janoshik Analytical Limited

For

BPC-157

by Hydro Research Peptides· batch HR-2026-4512

✓ Vendor-published
99.64 %
Jun 2026
Janoshik Analytical Limited

For

BPC-157

by optimasupply.is· batch OS-2026-3074

COA on file
Aggregated · 3rd-party listing
99.33 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Apexx Biolabs· batch Black Cap-1

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

BPC-157

by OROS Research· batch OR-LPBPC10-626-B6

✓ Vendor-published
99.80 %
Jun 2026
TrustPointe Analytics Moderate

For

BPC-157

by Peptide Partners· batch SPL-4161

COA on file
Aggregated · 3rd-party listing
99.28 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Rescue Research USA· batch WP-BPC-2606

Aggregated · 3rd-party listing
99.18 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Peptide Supply Co.· batch BC1006102026

✓ Vendor-published
99.43 %
Jun 2026
MZ Biolabs Moderate

For

BPC-157 (Bepecin) Arginine Salt

by Sports Technology Labs· batch 2026-05-30

COA on file
Aggregated · 3rd-party listing
99.61 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Modern Research Peptides· batch 225671F

Aggregated · 3rd-party listing
99.96 %
Jun 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch BPC20-05

Aggregated · 3rd-party listing
99.96 %
Jun 2026
ILS Labs Strong

For

BPC-157

by NG Peptide· batch BPC20-05

Aggregated · 3rd-party listing
99.11 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Peptide Plugs· batch GGB-03-BL

Aggregated · 3rd-party listing
99.86 %
Jun 2026
ILS Labs Strong

For

BPC-157

by Crush Research· batch CRBPC-10-2605-1

Aggregated · 3rd-party listing
99.18 %
Jun 2026
Freedom Diagnostics Moderate

For

BPC-157

by Nova Peptides· batch NV-P-2B1D

Research depth

20 citations indexed for BPC-157

All research on BPC-157 →

Study · 2026

Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel

Multifunctional hydrogels are essential for advanced biomedical applications. In this study, CH/BPC composite hydrogel was fabricated and characterized for their physicochemical properties.

Study · 2026

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase

Acetylcholinesterase (AChE) inhibition remains a key therapeutic strategy in the management of neurodegenerative disorders such as Alzheimer's disease.

animal · 2026

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

Objectives This study aims to evaluate the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in a rat model.

animal · 2026

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approach

Background . This rat study reveals a new point: the considerable impact of unilateral adrenalectomy, severe vascular and multiorgan failure, occlusion/occlusion-like syndrome, and the stable gastric pentadecapeptide BPC 157 therapy.

animal · 2026

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury

Ischemia-reperfusion (I/R) injury remains a major complication in peripheral arterial disease, characterized by oxidative stress, inflammation, and apoptosis. Body Protection Compound-157 (BPC 157), a stable gastric pentadecapeptide, has demonstrated cytoprotective properties in multiple tissues.

review · 2026

BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers

Background/Objectives : BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a gastric protein fragment with reported cytoprotective and regenerative properties across multiple organ systems.

Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.